Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications. Additionally, Xenetic is leveraging PolyXen(TM), its proprietary drug delivery platform, by partnering with biotechnology and pharmaceutical companies. PolyXen(TM) has demonstrated its ability to improve the half-life and other pharmacological properties of next-generation biologic drugs. The Company has an exclusive license agreement with Takeda Pharmaceuticals Co. Ltd. in the field of coagulation disorders and expects to earn royalty payments under this agreement.
| Revenue (Most Recent Fiscal Year) | $2.54M |
| Net Income (Most Recent Fiscal Year) | $-4.14M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 2.34 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.61 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -162.79% |
| Net Margin (Trailing 12 Months) | -162.84% |
| Return on Equity (Trailing 12 Months) | -36.43% |
| Return on Assets (Trailing 12 Months) | -33.74% |
| Current Ratio (Most Recent Fiscal Quarter) | 11.84 |
| Quick Ratio (Most Recent Fiscal Quarter) | 11.84 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.36 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.77 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.71 |
| Diluted Earnings per Share (Trailing 12 Months) | $-2.75 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 1.54M |
| Free Float | 1.40M |
| Market Capitalization | $5.93M |
| Average Volume (Last 20 Days) | 6658.85 |
| Beta (Past 60 Months) | 2.60 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 9.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 15.12% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |